NCT00583986View on ClinicalTrials.gov

Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

March 31, 2006

Conditions
AsthmaChronic Obstructive Pulmonary DiseaseCOPD
Interventions
DRUG

Levalbuterol HFA MDI with top mounted actuation indicator

Levalbuterol HFA MDA with top mounted actuation indicator

Trial Locations (26)

11725

Commack

14618

Rochester

19115

Philadelphia

22015

Burke

23225

Richmond

26505

Morgantown

27909

Elizabeth City

29681

Simpsonville

33321

Tamarac

37421

Chattanooga

73120

Oklahoma City

78130

Braunfels

78229

San Antonio

78750

Austin

92024

Encinatas

92120

San Diego

92506

Riverside

92626

Mesa

92647

Huntington Beach

92691

Viejo

92868

Orange County

94596

Walnut Creek

95128

San Jose

97213

Portland

97504

Medford

02747

Russells Mills

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00583986 - Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD | Biotech Hunter | Biotech Hunter